Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.74 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.50 |
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958328 | 0.86 | GPR52 (0.57) | GPR52NR4A2MRGPRX4KMOKDM4C | |
| SCHEMBL961978 | 0.85 | GPR52 (1.00) | GPR52MRGPRX4CDK8 | |
| SCHEMBL958231 | 0.84 | GPR52 (0.53) | GPR52MRGPRX4KMOLTB4R | |
| SCHEMBL960922 | 0.82 | GPR52 (0.81) | GPR52ALDH1A1CDK8 | |
| SCHEMBL961439 | 0.82 | GPR52 (0.52) | GPR52MRGPRX4KDM4CLTB4R | |
| SCHEMBL957828 | 0.79 | PTGDR (0.55) | GPR52MRGPRX4KDM4EALDH1A1KMT2A | |
| SCHEMBL958593 | 0.79 | GPR52 (0.53) | GPR52NR4A2MRGPRX4KMOKDM4C | |
| SCHEMBL961661 | 0.74 | GPR52 (0.52) | GPR52HDAC1HDAC6 | |
| SCHEMBL3994933 | 0.74 | ALDH1A1 (0.57) | GPR52NR4A2KMOKDM4EMEN1 | |
| SCHEMBL963457 | 0.74 | PTGDR (0.54) | GPR52NR4A2MRGPRX4KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | GPR52 23/4885NR4A2 8/4885MRGPRX4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.